| First Author | Meyskens FL Jr | Year | 2016 |
| Journal | J Natl Cancer Inst | Volume | 108 |
| Issue | 2 | PubMed ID | 26547931 |
| Mgi Jnum | J:237570 | Mgi Id | MGI:5816186 |
| Doi | 10.1093/jnci/djv309 | Citation | Meyskens FL Jr, et al. (2016) Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst 108(2) |
| abstractText | Approaches to reduce the global burden of cancer include two major strategies: screening and early detection and active preventive intervention. The latter is the topic of this Commentary and spans a broad range of activities. The genetic heterogeneity and complexity of advanced cancers strongly support the rationale for early interruption of the carcinogenic process and an enhanced focus on prevention as a priority strategy to reduce the burden of cancer; however, the focus of cancer prevention management should be on individuals at high risk and on primary localized disease in which screening and detection should also play a vital role. The timing and dose of (chemo-)preventive intervention also affects response. The intervention may be ineffective if the target population is very high risk or already presenting with preneoplastic lesions with cellular changes that cannot be reversed. The field needs to move beyond general concepts of carcinogenesis to targeted organ site prevention approaches in patients at high risk, as is currently being done for breast and colorectal cancers. Establishing the benefit of new cancer preventive interventions will take years and possibly decades, depending on the outcome being evaluated. We also propose that comparative effectiveness research designs and the value of information obtained from large-scale prevention studies are necessary in order for preventive interventions to become a routine part of cancer management. |
